American Association of Clinical Endocrinologists

Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates

Retrieved on: 
Tuesday, November 7, 2023
Research, Transgender hormone therapy, American Association of Clinical Endocrinologists, Event, Child, LUMO, Pediatric endocrinology, Therapy, City of Hope National Medical Center, Rare, IGFBP3, Mother, MD, Quarter, SDS, Endocrine Society, Clinical trial, PEM, KOL, Lumos, University, Serum, University of Chile, Political moderate, European Society of Gynaecological Oncology, Growth hormone, Investment, Consistency, AHV, Silviculture, Pharmaceutical industry, Birth control, Endocrinology

AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that topline results met primary and secondary endpoints for its Phase 2 Dose-Finding OraGrowtH210 Trial and Phase 2 Pharmacokinetic/Pharmacodynamic (PK/PD) OraGrowtH212 Trial evaluating oral LUM-201 for subjects with moderate pediatric growth hormone deficiency (PGHD) who screened PEM-positive utilizing Lumos Pharma’s predictive enrichment marker (PEM) strategy. Lumos also announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • Lumos also announced its financial results for the quarter ended September 30, 2023.
  • The Company expects cash use of approximately $9.0 to $10.0 million in the fourth quarter of 2023.
  • Net Loss – The net loss for the quarter ended September 30, 2023 was $8.3 million compared to a net loss of $7.3 million for the same period in 2022.
  • Lumos Pharma ended the third quarter 2023 with 7,914,582 shares outstanding.

New American Diabetes Association Report Finds Annual Costs of Diabetes to be $412.9 Billion

Retrieved on: 
Wednesday, November 1, 2023
Epidemiology, American Association of Clinical Endocrinologists, American Diabetes Association, African Americans, Physician, Prevalence, Workforce, Presenteeism, Death, Absenteeism, ADA, Economic cost, Unemployment, Woman, Economy, Blood, Insulin, Pharmaceutical industry, Dietary supplement, Health care, Diabetes

ARLINGTON, Va., Nov. 1, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) published the Economic Costs of Diabetes in the U.S. in 2022 (Economic Report), a comprehensive analysis assessing the financial burden of living with diabetes in the United States. The Economic Report, which is published every five years, found that the total annual cost of diabetes in 2022 is $412.9 billion, including $306.6 billion in direct medical costs and $106.3 billion in indirect costs. People with diagnosed diabetes now account for one of every four health care dollars spent in the U.S.

Key Points: 
  • The Economic Report, which is published every five years, found that the total annual cost of diabetes in 2022 is $412.9 billion, including $306.6 billion in direct medical costs and $106.3 billion in indirect costs.
  • The Economic Report includes data on diabetes prevalence, total direct medical costs, and average annual medical expenditures.
  • National health care costs attributable to diabetes have increased by $80 billion in the past 10 years—from $227 billion in 2012 to $307 billion in 2022.
  • The full Economic Costs of Diabetes in the US in 2022 report is available online and will appear in the December issue of ADA journal, Diabetes Care®.

Boston IVF Showcases Pioneering Fertility Research at the 2023 ASRM Scientific Congress & Expo

Retrieved on: 
Thursday, October 19, 2023
Embryology, Knowledge, Patient, Protocol, Research, Harvard Medical School, American Association of Clinical Endocrinologists, MPH, Beth Israel Deaconess Medical Center, Clinical research, Hope, RESEARCH, Congress, 2001 Slovenian fertility treatment referendum, Probability, Impact, MBA, Health, Episcopal conference, Society, Male, Reproductive medicine, IVF, Partnership, Abstract, Merck Serono, Cryopreservation, Comparison, American Society for Reproductive Medicine, ASRM, Expo, Diversity, IUI, Infertility, Nursing, Pharmaceutical industry, Mineral oil, Birth control, Fertility, MD, Doctor of Philosophy

BOSTON, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Boston IVF, a renowned leader in fertility research and patient care since its establishment in 1986, is proud to announce its substantial participation in the 2023 American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo. This prestigious annual event, in New Orleans, Louisiana, from October 14-18, brought together global experts to share groundbreaking advancements in technology, treatments, and patient care in reproductive medicine.

Key Points: 
  • Charting a Path to Tomorrow, Boston IVF's Groundbreaking Research in 2023 Continues to Shape the Future of Fertility Care
    BOSTON, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Boston IVF , a renowned leader in fertility research and patient care since its establishment in 1986, is proud to announce its substantial participation in the 2023 American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo .
  • – David Stern, CEO of Boston IVF
    Boston IVF's team of reproductive endocrinologists, scientists, clinicians, and researchers presented over 20 pioneering research studies, along with education symposia and roundtables.
  • This year, four distinguished individuals from Boston IVF were recognized nationally by the ASRM for their exceptional contributions:
    Yuval Fouks, MD, PhD, MPH a dedicated Research Fellow at Boston IVF, was honored with the ASRM 2023 IN TRAINING AWARD FOR RESEARCH for his noteworthy publication in Fertility and Sterility.
  • (Source: Fertility & Sterility)
    Quetrell Heyward, MD, MBA, a Reproductive Endocrinology and Infertility Fellow at Boston IVF & Beth Israel Deaconess Medical Center, received the prestigious ASRM 2023 INVESTIGATOR ACHIEVEMENT AWARD.

Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Retrieved on: 
Wednesday, October 11, 2023
General Health, Pharmaceutical, Health, Multimedia, Magnetic resonance imaging, Prescription, Weight loss, Crozer Health, Diabetes, NPS, Mouth, Medicine, PAS, HCP, Associate, Patient, MRI, Day, PCP, Concierge medicine, Nursing, Pharmaceutical industry, Health insurance, American Association of Clinical Endocrinologists, Cardiology, Semaglutide

View the full release here: https://www.businesswire.com/news/home/20231011843642/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231011843642/en/
    Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications (Graphic: Business Wire)
    Patients want prescription weight loss medications and HCPs are meeting their demands.
  • 89% of surveyed HCPs reported that they have seen a recent increase in patients proactively requesting prescription weight loss medications.
  • 92% of PCPs reported actively writing scripts for weight loss drugs or drugs with a weight loss benefit in the past year.
  • Sermo’s survey found that among patients who proactively request weight loss medications, 48% of surveyed HCPs reported that their patients only have brand awareness of Ozempic.

US Physicians Name Two Weight Loss Drugs as “Paradigm-Shifting,” While Cautioning on Safety and Cost, According to New InCrowd Report

Retrieved on: 
Tuesday, September 19, 2023
Diabetes, Fitness & Nutrition, Clinical Trials, Cardiology, Practice Management, Other Health, Biotechnology, Managed Care, Pharmaceutical, Health, Exercise, Semaglutide, Insurance, PCP, Public, Weight loss, CDC, Patient, Physician, Overweight, American Association of Clinical Endocrinologists, Fasting, Safety, Pharmaceutical industry, Nursing, Dietary supplement, Liraglutide

Data are from InCrowd , a real-time global data and insights provider to the healthcare and life sciences industry, and a brand of Apollo Intelligence (Apollo).

Key Points: 
  • Data are from InCrowd , a real-time global data and insights provider to the healthcare and life sciences industry, and a brand of Apollo Intelligence (Apollo).
  • Among weight loss drugs, doctors had the highest clinical familiarity with semaglutide (96%) as well with liraglutide, sold as Saxenda and Victosa (94%) in addition to tirzepatide (87%).
  • New medications in the market have shown wonderful response to therapeutic weight loss management with minimal side effects.
  • Each respondent has treated 20+ weight loss patients in the past month and prescribes prescription medications for weight loss.

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Maintenance, Ciba-Geigy Canada Ltd v Apotex Inc, Nephrology, Amgen, Policy, Myasthenia gravis, Ophthalmology, Immunomodulation, NMOSD, Patient, IgG4-related disease, Physician, Rheumatology, CAS, Growth, American Association of Clinical Endocrinologists, Neuromyelitis optica spectrum disorder, Pharmaceutical industry, TED

Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales.

Key Points: 
  • Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales.
  • Second-quarter and year-to-date 2022 UPLIZNA net sales included $8.6 million and $13.8 million, respectively, in international net sales.
  • The second-quarter results were driven by execution across all phases of the patient journey – demand generation, stakeholder education and adherence to treatment.
  • In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, the Company will not be hosting a conference call to discuss its financial results.

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

Retrieved on: 
Thursday, August 3, 2023
LSE, Chronic kidney disease, Life, Education, Hines, Quality of life, Type 2 diabetes, Loyola University, SALT, SGLT2, Associate, Dialysis, Ageing, Nephrology, Patient, Guideline, Practitioner, Physician, Risk, DKD, Research, Diabetic nephropathy, FDA, American Association of Clinical Endocrinologists, MPH, CKD, Loyola University Chicago, Kidney disease, Hypertension, Pharmaceutical industry

The confluence of new diagnostic technology, such as kidneyintelX.dkd, and new effective drug therapies, including SGLT2 inhibitors, has swung the door wide open to prevent millions of people from experiencing the life changing effects of uncontrolled kidney disease.

Key Points: 
  • The confluence of new diagnostic technology, such as kidneyintelX.dkd, and new effective drug therapies, including SGLT2 inhibitors, has swung the door wide open to prevent millions of people from experiencing the life changing effects of uncontrolled kidney disease.
  • Clinical actions are most effective for preserving kidney and cardiovascular health in DKD stages 1-3 before significant and irreversible kidney function loss has occurred.
  • Renalytix will engage with the Clinical Advisory Board to provide an urgent call to action for primary care clinicians to diagnose, risk assess and treat their patients with stage 1-3 CKD, specifically in type 2 diabetics.
  • The board will also advise the Company on education and outreach activities to promote adoption of best practices in kidney disease management, appropriate coordination with specialists including nephrologists and endocrinologists, and guideline recommendations.

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 2, 2023
Journal of Clinical Oncology, Doctor of Pharmacy, Depression, University, Prevalence, NASH, Diabetes, Anxiety, NDA, Syndrome, Neck, Corcept Therapeutics, PIN, Metabolism, MD, Investment, Physician, Cushing's syndrome, Patient, CORT, Liver, Growth, Ageing, American Association of Clinical Endocrinologists, Irritability, ALS, Fatigue, Prostate cancer, Pharmaceutical industry, Cryptocurrency

Corcept’s second quarter 2023 revenue was $117.7 million, compared to $103.4 million in the second quarter of 2022.

Key Points: 
  • Corcept’s second quarter 2023 revenue was $117.7 million, compared to $103.4 million in the second quarter of 2022.
  • Second quarter operating expenses were $88.1 million, compared to $72.0 million in the second quarter of 2022, due to increased spending on our development programs and to support the expansion of our clinical development and commercial teams.
  • Net income was $27.5 million in the second quarter of 2023 compared to $27.4 million in the same period last year.
  • In April 2023, Corcept purchased 6.6 million shares of its common stock for $145.4 million.

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

Retrieved on: 
Monday, July 31, 2023
KOL, MGH, Metabolism, Pituitary gland, Sequoyah, Clinical trial, Saint Andrew's Society, Medicine, Research, BSN, Harvard Medical School, Acromegaly, American Association of Clinical Endocrinologists, Patient, SAN, European Society of Endocrinology, Endocrine Society, Diagnosis, Hospital, Massachusetts General Hospital, Pharmaceutical industry, Adult, Endocrinology

(Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D.

Key Points: 
  • (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D.
  • and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands (SRLs).
  • Karen JP Liebert, R.N., B.S.N., is a research nurse / study coordinator in the Neuroendocrine Department at Massachusetts General Hospital (MGH).
  • She is a member of the Endocrine Nursing Society and has co-authored numerous peer-reviewed publications.

Less than half of endocrinologists are impressed with Tzield's ability to delay T1D (MARKETVUE® REPORT)

Retrieved on: 
Tuesday, July 11, 2023
Insulin, CD3, Pancreas, American Association of Clinical Endocrinologists, Patient, Physician, Risk, Immune system, Mab, REACH, Sanofi, FDA, Disease, Pharmaceutical industry, T1D, Teplizumab

NEWTON, Mass., July 11, 2023 /PRNewswire/ -- Type 1 Diabetes (T1D) is a life-long autoimmune disease where the immune system destroys the insulin-producing islet cells in the pancreas until they no longer produce insulin. To date, insulin replacement therapy has been the backbone of T1D treatment but has a significant treatment burden on patients. Recently, clinical development appears to be shifting towards therapies that could delay the need for insulin and preserve beta cell function.

Key Points: 
  • However, less than half of U.S. clinicians are impressed with the drug's ability to delay T1D onset, according to findings from REACH Market Research .
  • To date, insulin replacement therapy has been the backbone of T1D treatment but has a significant treatment burden on patients.
  • Recently, clinical development appears to be shifting towards therapies that could delay the need for insulin and preserve beta cell function.
  • Endocrinologist, U.S.: "What are the potential benefits of a drug like teplizumab in a person who has stage 2 diabetes?